Skip to main content
SpringerLink
Log in

Aripiprazole

In Adolescents with Schizophrenia

  • Adis Drug Profile
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

  • ▲ Aripiprazole is a novel atypical antipsychotic that is approved in the US for use in adolescents with schizophrenia.

  • ▲ In adolescents with schizophrenia, oral aripiprazole 10 or 30 mg/day lead to significantly greater reductions than placebo in the Positive and Negative Syndrome Scale (PANSS) total score from baseline to 6 weeks, according to findings from a randomized, double-blind, multicenter trial (n = 302).

  • ▲ In addition, aripiprazole 10 or 30 mg/day recipients had significantly greater improvements in the PANSS positive subscale and Clinical Global Impression-Severity and -Improvement scale scores than placebo recipients, and a significantly greater improvement in the PANSS negative subscale score was seen with aripiprazole 10 mg/day than with placebo.

  • ▲ Aripiprazole was generally well tolerated in adolescents with schizophrenia, with most adverse events being of mild to moderate severity. Clinically significant weight gain (≥7% as defined by the US FDA) occurred in 4.0% of aripiprazole 10 mg/day recipients, 5.2% of aripiprazole 30 mg/day recipients, and 1% of placebo recipients. The mean weight change was significantly different in aripiprazole and placebo recipients (0, +0.2, and −0.8kg in aripiprazole 10 mg/day, aripiprazole 30 mg/day, and placebo recipients, respectively).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Gillberg C, Wahlstrom J, Forsman A, et al. Teenage psychoses: epidemiology, classification and reduced optimality in the pre-, peri-, and neonatal periods. J Child Psychol Psychiatry 1986 Jan; 27(1): 87–98

    Article  PubMed  CAS  Google Scholar 

  2. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20(10): 841–66

    Article  PubMed  CAS  Google Scholar 

  3. Lenior ME, Dingemans PMAJ, Schene AH, et al. Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophr Bull 2005; 31(3): 781–91

    Article  PubMed  Google Scholar 

  4. McClellan J, Werry J. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2000 Dec; 39(12): 1580–2

    Article  Google Scholar 

  5. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20(5): 389–409

    Article  PubMed  CAS  Google Scholar 

  6. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. Epub 2007 Oct 8

    Google Scholar 

  7. Toren P, Ratner S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004; 27(14): 1135–56

    Article  PubMed  CAS  Google Scholar 

  8. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify® (aripiprazole) tablets prescribing information [online]. Available from URL: http://www.abilify.com [Accessed 2007 Nov 19]

  9. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64(15): 1715–36

    Article  PubMed  Google Scholar 

  10. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006 Feb; 39Suppl. 1: S21–5

    Article  PubMed  Google Scholar 

  11. Findling RL, Nyilas M, Auby P, et al. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia [abstract no. NR741 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)

  12. Correll CU, Mughal T, Parikh U, et al. Insulin resistance in treatment-naive youngsters treated with novel antipsychotics [abstract no. NR654 plus poster]. American Psychiatric Association Annual Meeting; 2005 May 21–26; Atlanta (GA)

  13. Blumer JL, Findling R, Kauffman R, et al. Pharmacokinetics, tolerability and safety of aripiprazole in children and adolescents with conduct disorder [abstract no. MPI-3]. Clin Pharmacol Ther 2002 Feb; 71: 5A

    Google Scholar 

  14. Findling RL, Auby P, Nyilas M, et al. Pharmacokinetics and tolerability of aripiprazole in children and adolescents with major psychiatric diagnoses [abstract no. NR654 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON)

  15. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004 Feb; 44(2): 179–87

    Article  PubMed  CAS  Google Scholar 

  16. Robb AS, Auby P, Nyilas M, et al. Efficacy of aripiprazole in the treatment of adolescents with schizophrenia [abstract no. NR742 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: A. Robb, Department of Child Psychiatry and Pediatrics, Children’s National Medical Center, Washington, DC, USA; P. Toren, Department of Child Psychiatry, Tel-Aviv Community Health Centre, Tel-Aviv University, Tel-Aviv, Israel.

During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article; changes based on any comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Mark Sanford & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Mark Sanford & Gillian M. Keating

Authors
  1. Mark Sanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Sanford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanford, M., Keating, G.M. Aripiprazole. Pediatr Drugs 9, 419–423 (2007). https://doi.org/10.2165/00148581-200709060-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200709060-00009

Keywords

Search

Navigation